Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab-IRDye800CW Imaging in Breast Cancer
NCT05359874Phase 2Withdrawn
- Sponsor
- Technical University of Munich
- Start
- Jun 2021
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of bevacizumab-IRDye800CW in breast cancer, ductal carcinoma in situ (DCIS), sponsored by Technical University of Munich. Planned start Jun 2021; status: withdrawn.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
breast cancerductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on NCT05359874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05359874.